258 results
8-K
EX-99.1
OGEN
Oragenics Inc
7 May 24
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
8:14am
and the potential benefits, activity, effectiveness and safety of its product candidates including as to administration, transmission, manufacturing
8-K
EX-99.1
OGEN
Oragenics Inc
18 Mar 24
Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion
7:38am
as to the outcome of the Phase II clinical trial and the potential benefits, activity, effectiveness and safety of its product candidates including
8-K
EX-1.1
OGEN
Oragenics Inc
1 Mar 24
Oragenics Announces Closing of Public Offering
4:05pm
carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and covering such risks which the Company believes … or liability, or action in respect thereof, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one
424B5
OGEN
Oragenics Inc
29 Feb 24
Prospectus supplement for primary offering
4:41pm
will become available and our research and development programs;
Our ability to timely and successfully achieve the anticipated benefits of acquiring … traumatic brain injuries also known as concussions;
Our expectations regarding the potential benefits, activity, effectiveness and safety of our product
8-K
EX-99.1
wc4wvq3zud31nzp56r
27 Feb 24
Oragenics Announces Proposed Public Offering
5:48pm
424B5
ysu 6gqpz61xkm8
27 Feb 24
Prospectus supplement for primary offering
5:04pm
8-K
c6p 5pcnwnnuqyvgh
12 Feb 24
Oragenics, Inc. Announces Leadership Transition
4:45pm
8-K
EX-99.1
uaptdbe2 pg1u
12 Feb 24
Oragenics, Inc. Announces Leadership Transition
4:45pm
8-K
EX-99.1
3b08h u8bkijl4
5 Feb 24
Other Events
8:00am
8-K
l1ueqj2
16 Jan 24
Other Events
9:10am
424B5
qwhx1q
16 Jan 24
Prospectus supplement for primary offering
9:04am
8-K
EX-99.1
srb5upsqxt300g
2 Jan 24
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
9:22am
8-K
EX-10.1
blzqf2 gj
29 Dec 23
Completion of Acquisition or Disposition of Assets
7:30am
8-K
q95zr9p6y
29 Dec 23
Completion of Acquisition or Disposition of Assets
7:30am
8-K
EX-4.1
iq72q euk7dqmrt2r
15 Dec 23
Material Modifications to Rights of Security Holders
3:45pm
8-K
EX-99.1
i56y 41egwcm4axmn
2 Nov 23
Oragenics Issues Update to Shareholders
7:00am
DEFA14A
a8e5kwwu4ai7ro
2 Nov 23
Additional proxy soliciting materials
7:00am